Okay, everyone, we're going to get started. My name is Van Holden. I'm the Program Director for PCCM Fellowship at the University of Maryland. I'm also an interventional pulmonologist. So this is one of my favorite topics is plural disorders. I'll be focusing on plural effusion today, particularly in how it relates to the ICU. So the objectives of my talk will be a classified plural fluid analysis.
describe management of transitive effusions, and then paradermonic effusions and empyema. So there's a very high volume of floral effusions nationally across the United States, greater than 1.5 million effusions a year, and up to more than half of critically ill patients can have an effusion. And in the ICU, it's most commonly due to volume overload, infection, malignancy, or an organ failure. So we're going to focus on the two most common ideologies, volume overload and floral infection. And it's important to note that pleurofusions in patients in the ICU have significantly higher morbidity and mortality than patients who don't have pleurofusions.
So patients with effusions in the ICU have higher short and long-term mortality. They have longer hospital and ICU length of stay. They have longer need for mechanical ventilation and duration of mechanical ventilation. And it's actually been shown that ICU patients who undergo parole procedures have worse outcomes than those who don't undergo parole procedures. And I thought about if they need a procedure, they're sick enough to need one. And so that further adds to the morbidity and mortality associated with it. So with that, I'm going to go to my first case.
So this is an 80-year-old with COPD, diabetes, hypertension, and phasional disease, and moderate aortic stenosis. He's coming in with dyspnea, and he's hypoxic, requiring non-invasive positive pressure ventilation, and is fighting a bilateral pleural effusion. This is a representation of an ultrasound image. And his history includes an ultrasound-guided thoracentesis bilaterally a month ago, and then a week later, he had a repeat one done on the left. So do you think the ultrasound image shows a simple or complicated pleural effusion? And you're welcome to unmute or use the chat box, whatever you prefer. Simple.
Simple, yeah, because it's completely black, anechoic. You can see this is a diaphragm here, this is the liver, and this is the lung. So how would you characterize his peripheral fluid analysis based on what you see here? Is it A, a transidate, B, an exudate, C, complicated exudate, D, pseudoexudate, or E, you don't have enough information? Someone says E, don't have enough information. Someone says need serum, protein, and LDH or cholesterol, so E. Okay, so we're going to – I'm not going to show you the right answer yet, but I will later.
So, why is it important to differentiate transidates from exudates? So, if you've determined that it's a transidate, you don't need to investigate further. Transidates are due to heart failure, liver failure, or kidney failure. And so, you treat and optimize the underlying disease. If it's an exudate, you're most likely concerned about cancer or infection. So, both of those need additional workup and intervention. So, it's important to know, thus, the criteria for exudates. And so, when you opted for E, in terms of needing serum protein and LDH, you're wanting that to calculate what? Life criteria.
Right. So for life criteria, if you have a theorem to pearl fluid total protein ratio greater than 0.5, LDH ratio greater than 0.6, or pearl fluid LDH greater than two-thirds upper limit of normal, any one of those would make it an exudate. However, there is also a three-step rule. So the three-step rule is if you have any one of these, it's also an exudate, and you only need pearl fluid sites. So a pearl fluid total protein greater than 2.9.
chlorofluid LDH greater than 0.45 at the limit of normal, or chlorofluid cholesterol greater than 45. Most of the time, I end up using just a three-step rule. It's just as sensitive and specific as life criteria without needing the serum values. And oftentimes, you may not have the serum LDH. Or there's a large timeframe between the serum, LDH, and total protein, and when the thorough fluid was drawn. But any one of these three criteria for the three-step rule works together as well. And I noticed in the chat, it also depends on if patients are on diuretics. And that's important to know, because you want to see whether or not it's a pseudoexidate. So a pseudoexidate is if someone's on diuretics are getting fluid removed, they're getting more volume removed than they are solute, solute fluid. So it falsely makes the solute values, like total protein or albumin, higher.
So a pseudoxidate is an albumin gradient greater than 1.2, zero minus pearl, or a total protein gradient greater than 3.1. And I recommend everyone to take a screenshot of this. I test my fellows on this pretty regularly when they're on the IT rotation. And it's very important because, again, it's going to point to whether any additional intervention is needed or do you focus on their underlying etiology. It's also good because we're going to get into prognosis in a little bit.
So in terms of pathophysiology, in terms of transidates, they could be due to high hydrostatic pressure, low oncotic pressure, or a shift of transidated fluids in the peritoneal state, for example, like the Psy-E's leading to the hepatic hydrothorax. heart failure, low albumin resulting in low and high pressure. So all of these can result in a transudated process. Whereas in an exudate, there is something wrong with the plurus. So either the lining of the plurus inflamed from cancer or infection, you have increased capillary permeability, or the plurus itself is infiltrated by tumor, there's lymphatic obstruction, so you have more fluid and protein in the plurus. But something's definitely wrong if it's truly an exudate.
So once you've determined, the first step is whether it's a transidate or an exudate. Then you can think about, well, what's the cause? What's the underlying etiology of these things? So as we mentioned, the most common causes of transidates, liver failure, heart failure, renal failure. Okay, heart, liver, lung. Less common causes could be low allumin levels, hypothyroidism, or mitral stenosis. If it's an exudate, something is wrong. Something is physically wrong with the flora, or there's inflammation infection. Most commonly, malignancy, paranoia confusion. Less likely, tuberculosis.
The other thing to be aware of, because we take care of patients in various ICUs, medical, surgical, neuro, a lot of different ICUs, other common etiologies of ICU diffusions is called a sympathetic effusion. And that can be a pancreatitis, post-MI, or post-cabbage. So in someone that has one of these effusions, a sympathetic effusion means that the pleura is very inflamed and reacting to a nearby inflamed organ. So whether it's a pancreas, it could be gall water, it could be pericarditis, or post-cardiac surgery. The lining of a nearby organ, or the organ itself, is inflamed, resulting in increased papillary permeability, and thus an excessive effusion. Those need to be drained. Because it's an inflamed effusion, if it's not drained, it can become septated, and will affiliate over time and cause problems.
The other reason why post-tabage effusions need to be drained are oftentimes they are bloody, particularly on the left side if they're harvesting the left internal mammary artery. And so those need to be drained before it becomes complex and septum. Other etiologies of S.A. diffusions are PE, rheumatoid arthritis, and BAPE, or benign asbestos effusions. So once you've determined transidate versus exudate, you want to see what the cell predominance is. So always, always get a cell count differential. So if it's lymphocyte predominant, meaning greater than 50% lymphocytes, it's most likely malignancy, actually, or a chronic longstanding pleural patient. So if someone has chronic heart failure or aortic stenosis or...
chronic hydrothorax or renal failure, long-term infusions tend to become lymphocytic over time. So you want to make sure that cytology is sent to make sure it's not underlying malignancy and it's just due to chronicity of the infusion. If you're worried about malignancy, when you send cytology, it identifies malignancy about 65% of the time with the first sample. You can send a second sample for cytology and it adds an additional 27% in diagnostic value, but after that, there's really no additional benefit. And if you have a strong suspicion for malignancy after you get a PET scan, then a probiopsy may be needed.
On the other hand, if someone has a neutrophil predominant portal fusion, then you're worried about infection, so most likely parenomonic infection. And if you see eosinophils, which means greater than 10% eosinophils, it's most likely air or blood in the portal space. So is it a hemothorax? Is it a hydronymothorax? And there's fluid and air. You can also see eosinophilic portal fusions of its drug-induced piracy. So we've seen this in oncology patients who've been on immunotherapy, and they have a drug reaction. You can also be worried about parasitic diseases or lymphoma.
And then there's some special conditions just to be aware of. So rheumatoid arthritis-associated prolifusions are such as very low glucose levels, glucose less than 29. They can also have very low pH levels. And someone with a tuberculosis prolifusion, you want to send adenosine deaminase. Adenosine deaminase is greater than 40 units per liter's diagnostic. If you're worried about hemothorax, you want to send to prolifluid hematocrit. So if someone comes in, has a broken rib, and there's a prolifusion, it could be a sympathetic prolifusion because of the broken rib that's inflamed, or maybe there's a vessel injury and it's a hemothorax. So you can send to prolifluid hematocrit.
Patients have urinary obstruction with chylonecritus. They can get a urinal thorax and it's in profluid creatinine. And then there's something called a chylothorax in which the fluid looks very milky and profluid triglycerides greater than 110 are diagnostic of that. Again, the goal of any time you obtain body fluid, your goal is to find out what's wrong and send it for the right test. It's much easier sending all these tests up front if you have suspicion for them and trying to add them on afterwards. So going back to our case, this patient has NSAID renal disease.
moderate aortic stenosis, and he's had bilayer plurifusions, which have both been dreamed. So going back to our question, how would you characterize the plurifluid? A, transidate, B, exudate, C, complicated exudate, D, pseudoexudate, or you don't have that infusion. Based on the three-step rule. Transidate. Yep. A. So it is a lymphocyte-predominant transidative effusion, likely from either renal disease or the moderate aortic stenosis.
And it's important to know that even though it's a transitive effusion, most of the time you think about, oh, it's benign, but it's not actually that benign. So if you have bilateral transitive effusions, it's about a 50% one-year mortality. So patients have a very poor prognosis. And it's because they have these effusions due to organ dysfunction, so either heart, lung, liver. If they have four underlying organ dysfunction, they have a 50% one-year mortality. So it's also important to consider getting palliative care involved.
So the management of the, quote, benign, or floral effusion, is you're going to treat the underlying etiology. So getting a repeat echo, seeing a new orcinosis got worse, so they need an intervention on the valve. Can their dialysis get optimized? You can do a repeat thorax or symptomatic. If they're refractory, you can consider doing an indwelling floral catheter. In the acute setting, so this patient when they're non-invasive, positive pressure ventilation, you could do a thorax and a temporized thing to see if she gets better.
Or you can also put it in a pigtail until the underlying etiology is maximally treated. And once that's done and she still has an infusion, then consider indwelling oral catheter. So, indoor and pearl catheters can be used in refractory effusions due to heart failure or renal failure. And this is actually pretty safe. There's a very low rate of skin infections and empyema that's considered acceptable, which is usually less than 5%. So, indoor and pearl catheters are an option. However, you would not want to do it in hepatic hydrothorax. So, when someone who's in an ICU may potentially be evaluating a liver transplant, sometimes we get asked about how do you manage a hepatic hydrothorax while they're undergoing liver transplant evaluation.
And typically, you don't want to leave a tube, especially in the pearl phase. So a tunneled flying, like a tunneled pearl catheter, is supposed to have less infection risk than a pigtail. But even with a tunneled catheter, the pearl fluid infection rate was 17% in this one study. And it's very morbid and associated with high mortality in this patient population. In another study that had 10% risk of pearl phase infection, again, some catheter-related stuff is leading to death occurred, as well as sedulitis and paramedic effusion and empyema.
So specifically for patients with a hepatic hydrothrax, that is an indication for liver transplant evaluation because it's inorgan failure of the liver. You want to treat them with sodium restriction, diuretics. If they have good response, they continue with their diuretics. If they don't respond, then do periodic thoracinthesis or symptom management. If they don't respond to that, you can consider TIPs. However, there's a higher risk of hypoglyphalopathy, but it does work. If they don't respond with bite TIPs, then more frequent thoracinthesis. But again, ideally, the ultimate treatment is liver transplant.
If they are not a candidate for liver transplant and they are considered palliative or heading towards end of life, then a tunnel catheter could be considered for palliation. Again, with the understanding that it has a very high infection. So case two, we have a 74-year-old with a history of kidney transplant on immunodepression, diabetes, hypertension, hyperlipidemia, coming in with fever, productive cough, and left-sided chest pain for two weeks. He's febrile, tachycardic, and hypotensive. And this is what his chest x-ray looks like and his CT scan showing loculations of the left pearl face.
He gets a drain, and how would you characterize the peripheral fluid in this patient? We're going to go over this as well. So this patient has a terapneumonic effusion, and this is what you'd most likely see with effusions in the ICU after volume overload. And the severity of terapneumonic effusions depends on the timing of the presentation. Do they come immediately after they start having symptoms of pneumonia, or do they wait to see if they would get better in wait a day or even a few weeks before coming in?
Patients will often have pleuritic check dates. So anytime someone has checked pain, that means the pleura is very inflamed. It's most likely related to keratomotic effusion. It could be complicated. How long have they had a fever? And there's other predictors of keratomotic effusions as well. Based on imaging studies, you can initially categorize them as small, moderate, or large. Finally, when I look with ultrasound, I see if they're having complex features, like the patient and the population. Patients don't need a CT chest with contrast. If they happen to get one for another reason, for example, to look for a PE.
You might see plural enhancements or split plural signs. So we discussed a little bit about this, but what plural fluid test would you always want to order? And I know you should probably never say always, but I mean this is always. What would you always want to order? pH. pH, yep. What else? Fulture? Glucose? AFD?
And we're going to go over this because it's so important to send the studies up front. So these tests always, always should be sent. Okay, so cell count and differential, again, because you can differentiate where the etiologies of the fusion, pH, glucose, LDH, that can tell you whether it's simple or complicated, XE, the total protein, albumin, you can see whether it's etorexity, cholesterol, gram state and culture, and cytology. So actually based on British Thoracic Society guidelines, cytology is actually always recommended. And the reason for that is because About 5% of transitive effusions are actually malignant. And also what you think is a terapneumonic pneumonia could be cancer. So that lung consolidation could be malignancy. So studying cytology is very helpful. They can also stain the cytology for organisms as well.
In terms of things that you could consider sending with the immunocompromised, like this patient who has a kidney transplant, you want to send for AFB-stating culture and fungal-stating culture. And the reason for this is we've had cases of reactivation TB in lung cancer patients who've been on chemotherapy, and they've presented as tuberculosis effusion. So these patients who are immunocompromised are at higher risk of these unusual pro-infections. When you're worried about floral infections, it's best to send the fluid down to the lab in blood culture bottles because you're more likely to get diagnostic cancer. So, floral fluid cultures are actually negative like 40% of the time, so it's very hard to identify and do susceptibility testing on the organism. But sending it in blood culture bottles helps identify the answer.
So to determine how to treat paramedic infusions, we're going to go over the different stages. So there's stage 1, 2, 3, and 4, and this is based on CHEC guidelines in 2000. And there's a question, is ADA recommended in addition to AFP standard culture? So ADA would be recommended if you have a high suspicion that it's a tuberculous pleural infusion, for example, patients who have risk factors for it, who have signs and symptoms concerning for it, then I would also obtain it. Because it also takes about a few days for the ADA legal to come back.
So the stages of complicated paradigmatic effusions and empyema, so stage one, meaning very low risk for morbidity and mortality, so stage one is an uncomplicated effusion. It's very small, less than a centimeter, free-flowing. You don't need to drain those. So those are very small. Considered trace pro effusions. They're too small to drain. The next step is now it starts to get small to moderate. It's greater than a centimeter, up to half of the hemothorax. The pH and glucose are normal. You could drain that simply with a thoracin tupus.
So, if it's small and moderate, drain completely with a thorax. Now, if it's complicated, meaning it's large, greater than half of the chest, it's loculated, the pleural is thickant, or they have any of these bad pro-fluid analysis studies, be a chest tube. The chest tube needs to be in to completely drain the effusion. And what makes the pleural effusion complicated is, and this is important to know, pH less than 7.2, glucose less than 60, or LDH greater than 1,000. So low pH, low glucose, high LDH. Because any of those markers would also indicate the need for intrapleural fibrinoids. And then lastly, stage 4, high-risk empyre, meaning they have frank pus.
Now, if you note, these guidelines are very old. They're from 2000. It's been more than 20 years since these initial guidelines have come out. We need updated guidelines, even British arrest society guidelines from 2010. Updates are currently in place for that. And what this does not include is our ultrasound characteristics. And what you don't want to do is do something called a diagnostic aspiration, and you stick a small needle into the pearl space just to get enough sample, send it to the lab, and see, okay, my pH is 7.1, so now I'm going to do check two.
or pH is 7.4, so now I'm just into a thora and drain the fluid completely. The risk associated with the procedure is every time you enter into the thorough space. So you'll want to definitively up front decide on doing a thora and drain completely, or do a chest tube and leave it in. But never do a, quote, diagnostic sample to obtain 20 or 30 seconds of fluid to send to the lab. Drain completely.
If you start with a thora and you realize that, oh, you're actually aspirating pus, you can always convert the thora synthesis to a pigtel. And the way that you would do that is you would advance a guide wire through your thora synthesis catheter into the pearl space and then use that to convert to a shut tube or pigtel. So based on ultrasound features, you can see similar to our first patient who had a completely anechoic clorofusion, anechoic effusion can be either candidative or effedative. But any time you have complexity to the effusion like this, there's increased density to the effusion, there's septations, or it's completely echogenic, these are most likely to be effed. And in this study, they were almost always effed. And so you can use that to help determine whether you would start with Adora or do it to tell.
In addition to stages of pereinamide diffusion and empanema, just to reinforce what we discussed, so stage one is an uncomplicated exudative effusion. Patients typically present within a few days, so these are simple exudative effusions. They have normal pH and glucose, they have no positive Gramscian culture, and they're small to moderate in size and free flowing. If they present days to weeks, then the fluid starts to become sick, inflamed. They have high serum WBC, they can have high pro-fluid LDH, low pH, low glucose.
The pearl fluid gram stain and culture could be positive. These could be the large, free-flowing or loculating diffusions with pearl thickening. And then finally, the late stage is an organized phase where you have a thick, fibrous peel. And in this image, there's a pixel in place, and it's completely black because it's a trapped lung with a thick rind. And so determining which stage the patient is in will help determine your management. In all of these stages, antibiotics are definitely needed. So if it's early, stage one, you can drain them if they're symptomatic.
If they're complicated, meaning high LDH, low pH, low glucose, you need a chest tube. And fibrinolyics, most of the time. If they have a thick pleural rind, that's when you would consider surgery. Because surgeons can do decortication where they peel off their rind to help the lung expand. It's important to have a multidisciplinary approach to these patients. Arthoretic surgeons like to have a pixel in place with some intraperial fibrinolytics up front to help clean the space out, even if it's a trapped lung, in order to prepare them for surgery.
So this also helps you determine whether you need to do a thoracic or a chest tube. In terms of antibiotics for all of these patients, think about whether it's community-acquired, teratomotic infusion, or emplenema, or is it hospital-acquired? So anything that's community-acquired is most likely strep. So it's going to be similar to your organisms that cause pneumonia, plus anaerobes. Maybe they're at risk of aspiration. So community-acquired must cover strep. If it's hospital-acquired, you may have some sort of surgical procedure intervention, and it's most likely staph. So make sure you cover strep and staph.
And then how do patients typically get these inspected pearl spaces? So, number one is most likely, again, from an amelian, so pera-namelian infection. They can also get inspected pearl spaces from hematogenous spread or direct inoculation with recent trauma or surgery. They can have translocation from subdiabromatic organisms. They can have neocinitis that's been spread into the pearl space or reactivation of infection, such as tuberculosis.
Think about when you're in a SICU, there's a lot of other things that can cause inspected pleural effusions, such as esophageal rupture. You have sub-diaphragmatic abscesses, splenic abscesses, so pyrolytic ericarditis. So any infection of a nearby organ can cause sympathetic effusions, which are inflamed infusions, but they can also progress to inspected effusions. So the treatment of them, you want to make sure you cover antibiotics, completely drain the pleural space with a chest tube or a bath, give them fibrinolix. So if you look at guidelines, because they're outdated, they actually did not include fibrinolytics, but the fibrinolytics were first studied back in 2011 with the MIST protocol.
With emphyema, because it is frank pus or frank infection, you want to make sure it's completely clear. That means obtaining a repeat CC chest before removing a chest tube. You also want to make sure that the output of a chest tube is less than 50 CCs within a day. So based on these studies, they're cut off with less than 50 CCs in a day. So those are common questions we get asked, is when can the tube come out? You need to repeat a CT scan and then you have low chest tube output.
There's also been a recent statement on the use of fibrinolytics and DNAs in patients with pleural enpanema. You can give the recommended dose, which is 10 over 5 milligrams, together with one-hour dwell time twice a day. They suggest that the number of doses be individualized based on the patient. So in the original study, the patients got doses twice a day for three days, so a total of six doses. Most of the time, patients only need two to three doses. So the need for additional doses depends on their clinical status and imaging studies. If there's any residual effusion, they still have a white count, they're still a febrile or a tachycardic, keep giving them doses until the oral space is clear. One of the questions is, would you consider large check tubes greater than 14 French? So I would say no. There is also another study comparing different size check tubes for the management of empyema. And a 14 French check tube, actually called a 14 French check tube, works just as well.
larger-sized chest tubes, and it's more comfortable for the patient. So the only thing that the large chest tubes have shown based on studies is actually the patients with higher pain scores, and those chest tubes are actually in for a longer period of time, and it prolongs their hospitalization. So pigtails or smaller tubes are actually easier to manage, and they're more comfortable for the patient. The maximum number of PCA during these treatments. So based on the misstudy, it was six studies. And if they are not improved after that, it would be a discussion with thoracic surgery to see if at that point they would want to do a vaccine and clean out the floral space. If the patient is higher risk for surgery, meaning they're not good surgical candidates, you can keep giving additional doses. It's not studied, but it's weighing the risk benefits of less invasive therapy. Have we given more than six doses? Yes, but rarely.
Any comment on pearl irrigation for patients who are candidates for TPA, DNA, or VATs? Yes. So, in patients who are not candidates for TPA or VATs, there's another study showing pearl irrigation with normal saline. So, I believe there was 100 milliliters of normal saline three times a day. And the thought of that is if you have normal saline, you're diluting out the empyema. It makes it easier to drain. You're kind of washing out the pearl space using the tube that's in place. So, you can also consider doing that.
Patients who are not candidates for TPA and DNA would be, I would say, if they're severely thrombocytinic, they're on anti-flagulation or they have flageopathy that can't be reversed or stopped. The main concern with TPA, intrapural TPA, is there's a 5% risk of plural bleeding. That 5% plural bleeding can be mild, like where the fluid turns red, but it's still free-flowing. But it can be as severe as needing blood transfusion or surgical intervention. So the main concern with TPA is looking at their platelet count, INR levels. Are there any other risk factors for bleeding?
The initial approach for fibrinoidic therapy is if they're in stage 2, empyema. But once they have the organized floral rhymes, then that is recommended. And someone with a pteranomia diffusion at empyema can calculate their rapid score. So patients with this sort of infection, it's actually associated with pretty poor mortality. So if they have a low rapid score, they might have a good 3-month prognosis. If they have a medium score of 3-4, then their 3-month mortality is 9-12%.
If their score is 5 to 7, they have a really high incidence mortality. This needs to be prospectively validated to see what do you do with this information. What do you do knowing the prognosis? For example, if someone is at high risk, would you want to be more aggressive and offer surgery to give them the best chance or not? Because we really don't know yet whether surgery is superior to intracurial fibromyalgia therapy.
So how would you characterize the furrow fluid? So this patient has a complicated exudate because the glucose is very low, it's less than 60, and the LDH is very high, it's less than, or greater than 1,000. So for a complicated exudate, how would you manage the infusion? I think the cancers already showed up, but chesty. So this is a loculated infusion. You may not know what the furrow fluid studies will show, but based on loculations or presence of septations or echogenicity, you're in place to chesty first.
So we're going to spend the last time discussing oral procedures, which we would do often in the ICU. But also, it's important to know what the potential complications of them could be and how do you minimize the risk of those complications. So any oral procedure associated complication includes pneumothorax, bleeding, and re-fansion pulmonary edema. So the risk of pneumothorax is higher the more number of passes you go through the skin. So similar to insidation. If you have a learner, you can try once, maybe twice, then the more senior person will go for the third time. Because the more number of passes through the skin increases the risk of lung injury as well as bleeding competition.
Re-expansion pulmonary edema, so it used to be thought that you should only remove a certain amount of fluid, whether it's 1.5 liters or 2 liters, because you could develop re-expansion pulmonary edema. This has actually been debunked, I would say. So re-expansion pulmonary edema develops more due to the negative pressure as you're draining the fluid. So if you're hand pumping the fluid during a thoracetesis, you can generate very highly negative intrapural pressures, and that is what causes re-expansion pulmonary edema. For all of you, since you're ICU fellows, you're probably very comfortable using ultrasound. Ultrasound is a month-ready pearl procedure. It's been demonstrated to have higher success of aspirating pearl fluid. So oftentimes we will use ultrasound to mark a spot. We'll go in with a needle. If we don't get fluid, then we will put an ultrasound probe cover on and check in real time. Ultrasound can also be used to characterize the pearl fusion. You can estimate how much fluid is there with receptations, and there's less complications with using ultrasound.
And one of the main complications that we're most worried about that's associated with mortality is injuries in the vessels. Okay, so intercostal arteries. The more lateral you are, the less variability there is in the intercostal artery. So if you're three centimeters lateral to the spine, the intercostal artery was shielded by the rib only about 17% of the time. But the more lateral you are, the more the intercostal artery is tucked underneath the rib and shielded. So go as lateral as you can.
And someone that has had imaging studies with contrast, they're looking at their coronal images, and sometimes they can actually identify the intercostal arteries in their path before doing their procedure. It's also important to know that there could be collateral arteries. So the collateral arteries branch off of the intercostal arteries, about four to five centimeters lateral from the spine. And so these vessels could also be injured. So they want to go lateral. And something that could be helpful is to use ultrasound to try to identify the intercostal arteries.
So you can use a linear probe, turn your Doppler on, and you can see in this image that the intercostal vessels are right underneath the rib, whereas in this image, the intercostal vessel is right in the middle of that rib space. So use an ultrasound to try to identify themselves, especially in high-risk patients. So high-risk patients mean that they have very small rib spaces. They could be obese. Maybe they're on dual type platelet therapy. So you're going to be particularly cautious in that patient population.
And in the real world, they actually studied this in physicians using the curvilinear probe parallel to the ribs with no training. These were respiratory physicians and trainees. They weren't taught how to do this. They were just taught to use the probe and try to identify the vessels. And when they did that, they were able to identify them in about half of cases. And when they did find them, they changed where they would enter in 30% of the cases. So again, I highly encourage you to start trying this and seeing if you can identify the intercopal vessels and if that changes your management and where you would go for the fluid.
Using ultrasound is also helpful to estimate how much fluid is there. So in patients that have a very small amount of fluid, usually less than 500 cc of fluid, they typically don't have symptomatic relief. So if it's a very small, simple curing effusion, it may not necessarily need to be drained. So to estimate how much fluid is there, you're going to measure the difference between the parietal and visceral quora in inspiration, so the distance from the diaphragm to the lungs, and take it times 20. When you take it times 20, that gives you the approximate volume.
This is also helpful because, for example, if you estimate maybe there's 800 cc of fluid there, you know when you're going to be expecting to terminate drainage, when you think it might be done, when there's no more fluid left. But if you drain a lot more than that and the fluid is now getting bloodier, you'll be worried about vessel injury and a hemoglobin. There are guidelines on managing blood thinners and anti-platelet medications for oral procedures. So, foral procedure is actually considered a high-risk bleeding procedure. So, thorax or foral procedure is greater than two. Ideally, those should be reversed, especially in a non-emergent setting. Pletelet bowls is greater than 50,000. If it's an elective procedure holding propletogrel, aspirin is not going to be held, and their acute anticoagulation should be held.
There are very small studies looking at flow procedures on patients on dual antiplatelet therapy, and they're very small studies. And so it's still recommended that unless it's urgent or emergent, we should hold clopidogrel for five to seven days before the procedure and hold anticoagulation, again, in a non-emergent study. So just to summarize, we went over thorough fluid analysis, so make sure you send all the appropriate tests up front. Determine whether it's an effidate or transidate. Look at the cell count and differential. Determine the etiology of the effusion. If it's a transitive effusion, then it's either heart, liver, or kidney failure. Treat the underlying etiology. They also have 50% one-year mortality. Drating the effusion if they're symptomatic.
If it's a keratomonic pleural effusion or empyema, use your ultrasound. Look for any complex features. Then determine whether you need a thora or a chest tube. If they need antibiotics, based on profile analysis or any complex features, they may need interprofile fibrinolytics. Make sure that these effusions are drained completely before removing the tube. Less than 50cc. If it's a thickened pleural rind or trapped lung, then that's thoracic surgery. That's it. I'm happy to take any questions.